Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.15, $0.05 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $51.1 million.

GUIDANCE:

Meridian Bioscience sees FY2017 EPS of $0.64-$0.69, versus the consensus of $0.82. Meridian Bioscience sees FY2017 revenue of $193-199 million, versus the consensus of $206.1 million.

Revised the fiscal 2017 annual indicated cash dividend rate to $0.50 per share, and declared the regular quarterly cash dividend of $0.125 per share for the first quarter of fiscal 2017 (annual indicated rate of $0.50 per share);

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.